EUVIMEDEUVIMED entdecken
Crossref

Hepatotoxicity in patients undergoing systemic treatment with Ribociclib

C. Bambey, K. Smetanay, C. Fremd, V. Thewes, A. Schneeweiss, L. Michel

Senologie - Zeitschrift für Mammadiagnostik und -therapie · 01.06.2024 · 21 (02) · e2

DOI: 10.1055/s-0044-1786071 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Senologie - Zeitschrift für Mammadiagnostik und -therapie, erschienen am 01.06.2024. Verfasst von C. Bambey und 5 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Only scarce data exists regarding hepatoxicity in patients (pts) undergoing treatment with Ribociclib. Material and methods: We performed a retrospective chart review of 68 hormone receptor-positive metastatic breast cancer pts, who were treated with Ribociclib between 2017 and 2023. Liver enzymes were evaluated at baseline and during therapy by Common Terminology Criteria for Adverse Events version 5.0 (CTCAEv5.0).

Results

23 pts were excluded because of missing follow-up data. 45 pts were included into analysis. Median age was 56 years (range 27-83). At baseline, 19/45 (42%) pts presented with liver metastasis and 14 of them had elevated liver enzymes. At data cut off (22.1.2024) 20/45 pts were still on treatment. Elevation of liver enzymes of more than one grade was observed in 8/45 (18%) pts (maximal grades: 1=1 pt; 2=2 pts; 3=2 pts; 4=3 pts). 2 of them had hepatic metastasis (both liver enzymes max. grade 3). Treatment associated liver toxicity was histologically confirmed in 2 pts by liver biopsy. In 7/8 pts treatment with Ribociclib was discontinued. The average duration was 86 days until liver enzymes declined and 133 days until all pts declined to grade 1. None of the pts had disease progression during this period. 4/7 pts continued with Abemaciclib, without further relevant liver toxicity.

Conclusion

Therapy with Ribociclib treatment causes liver enzyme elevation in a substantial number of pts which might require treatment discontinuation. Further studies should examine the underlying mechanism and potential risk factors. After decline of liver enzymes switch to an Abemaciclib is possible. Publication History Article published online: 03 May 2024 © 2024. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

Zitieren

APA

Bambey, C., Smetanay, K., Fremd, C., Thewes, V., Schneeweiss, A., & Michel, L. (2024). Hepatotoxicity in patients undergoing systemic treatment with Ribociclib. Senologie - Zeitschrift für Mammadiagnostik und -therapie, 21(02), e2. https://doi.org/10.1055/s-0044-1786071

Vancouver

Bambey C, Smetanay K, Fremd C, Thewes V, Schneeweiss A, Michel L. Hepatotoxicity in patients undergoing systemic treatment with Ribociclib. Senologie - Zeitschrift für Mammadiagnostik und -therapie. 2024;21(02):e2. doi:10.1055/s-0044-1786071

BibTeX
@article{Bambey2024,
  author = {Bambey, C. and Smetanay, K. and Fremd, C. and Thewes, V. and Schneeweiss, A. and Michel, L.},
  title = {Hepatotoxicity in patients undergoing systemic treatment with Ribociclib},
  journal = {Senologie - Zeitschrift für Mammadiagnostik und -therapie},
  year = {2024},
  volume = {21},
  number = {02},
  pages = {e2},
  doi = {10.1055/s-0044-1786071}
}
Kostenlos starten →